PAK5 and melanoma: To determine whether melanoma-common PAK5 mutants confer resistance to temozolomide, an alkylating chemotherapeutic drug approved for the treatment of malignant melanoma [57], we first ascertained the IC50 of temozolomide in hMELT cells expressing wildtype PAK5 (250 μM; Figure 3D).